CanSino taps Aerogen for development, commercial supply of inhaled COVID-19 vaccine hopeful
CanSino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable. Because aerosol delivery requires a "considerably smaller volume of vaccine," the partners' inhaled prospect could help stretch capacity and enable more patients to access the inoculation, the companies said.